

## INVESTOR WEBINAR – BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") is pleased to announce that its CEO Dr Alexandra Andrews will be holding a live investor webinar on **Friday 8th July 2022 from 11:00am AWST / 1:00pm AEST**. The webinar format will comprise of a 15 minute presentation and 20 minute live Q & A.

Dr Andrews will provide an update on the Company's landmark paediatric Autism Spectrum Disorder (ASD) study at Monash Children's Hospital in Melbourne and discuss the recently announced Phase I/II clinical trial results (ASX Announcement dated 8 July 2022).

To access the webinar, please copy and paste the following link into your internet browser:  
<https://attendee.gotowebinar.com/register/2732683742910510862>.

### Authority

This announcement has been authorised for release by the Chairman of Neurotech International Limited.

### Further Information

Dr Alexandra Andrews  
CEO

[aa@neurotechinternational.com](mailto:aa@neurotechinternational.com)

+61 (0)405 339 788

Brian Leedman  
Chairman

[b.leedman@neurotechinternational.com](mailto:b.leedman@neurotechinternational.com)

+61 (0)41 228 1780

### Media:

Amalie Schreurs

White Noise Communications

[amalie@whitenoisecomms.com](mailto:amalie@whitenoisecomms.com)

+61 (0)431 636 033

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a biopharmaceutical company focused on the development and commercialisation of neurological solutions that improve quality of life. Neurotech is currently conducting a world-first clinical trial to assess the potential application of NTI164 for the treatment of Autism Spectrum Disorder (ASD). Results of Phase I/II indicated that 93% of participants had notable improvements relating to the severity of illness with no serious side effects. The next step will be initiation of Phase II/III of the trial to further assess the long-term safety and efficacy of NTI164, with the potential to lead to drug registration. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.